⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
globenewswire.com
AZN
NVS
ABBV
BMY
GILD
REGN
VRTX
BIIB
JNJ
MRK
ARWR
TAK
VERA
TransCelerate Receives DIA Global Inspire Award and Showcases Collaborative Innovation at DIA 2026
prnewswire.com
NVS
GILD
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
businesswire.com
GILD
MRK
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
businesswire.com
GILD
MRK
Retool Achieves AWS Consumer Goods Competency
businesswire.com
AMZN
COIN
DDOG
ADBE
NFLX
AAPL
GOOG
CHTR
NVDA
MSFT
INTC
AMD
TSLA
META
CRM
IBM
ORCL
CSCO
ACN
PYPL
UPST
PLTR
SNOW
CRWD
PANW
ZS
MDB
AFRM
SOFI
UPWK
FIVN
DOCU
SMCI
ASML
AMAT
KLAC
LRCX
MU
WDC
NXPI
QCOM
MRVL
ADSK
CDNS
SNPS
AMGN
GILD
BMY
LLY
REGN
VRTX
BIIB
AZN
XOM
CVX
SHEL
T
VZ
TMUS
CMCSA
DIS
GOOGL
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
accessnewswire.com
NNVC
GILD
Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic
prnewswire.com
GILD
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
businesswire.com
GILD
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
globenewswire.com
GILD
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
businesswire.com
GILD
LKFT